Primary Biliary Cholangitis (PBC)Phase 2NCT07678645
The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
A Phase 2 study testing Upadacitinib 15 MG in people with Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC), run by RenJi Hospital at 1 site in China.
Trial summary
Cholestatic liver diseases are characterized by jaundice, pruritus, and elevated levels of alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT). Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) represent the major autoimmune-driven entities within this category. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Atopic Dermatitis (AD)
- What is being tested?
- Upadacitinib 15 MG
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 44 participants
- Where
- 1 siteChina
- Study dates
- 1 Jun 2026to 31 May 2028
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients must meet all of the following criteria to be eligible for enrollment:
- Aged ≥18 and ≤70 years, of either sex.
- Criteria for Atopic Dermatitis (AD)
- Diagnosis of AD according to the Chinese diagnostic criteria for adult AD, defined as meeting the primary criterion (a) plus either criterion (b) or (c) below:
- Presence of symmetrical eczema with a disease duration of more than 6 months.
- Personal and/or first-degree family history of atopic diseases (e.g., eczema, allergic rhinitis, asthma, allergic conjunctivitis, etc.).
Show all 24Show fewer
- At least one of the following laboratory findings: elevated serum total immunoglobulin E (IgE), elevated peripheral blood eosinophil count, or positive allergen-specific IgE.
- Presence of moderate-to-severe pruritus, defined as a Visual Analogue Scale (VAS) score ≥4.
- Criteria for Primary Biliary Cholangitis (PBC)
- Diagnosis of PBC according to practice guideline criteria, defined as meeting at least two of the following three criteria:
- Biochemical evidence of cholestasis, primarily elevated alkaline phosphatase (ALP) and/or gamma-glutamyl transferase (GGT).
- Positivity for anti-mitochondrial antibody (AMA) or AMA-M2, or positivity for other disease-specific autoantibodies (anti-gp210 or anti-sp100 antibodies).
- Histological evidence of non-suppurative destructive cholangitis and small bile duct destruction.
- Patients must have received a standard regimen of ursodeoxycholic acid (UDCA) for ≥12 months (at a dose of no less than 13-15 mg/kg/day) in combination with at least two subsequent-line therapies (including Farnesoid X receptor agonists, peroxisome proliferator-activated receptor agonists, budesonide, or other immunosuppressants) for ≥3 months.
- At screening, ALP ≥1.5 × upper limit of normal (ULN) or GGT ≥5 × ULN.
- Criteria for Primary Sclerosing Cholangitis (PSC)
- For large-duct PSC, diagnosis must meet the following criteria:
- Biliary imaging showing characteristic multifocal, short-segmental, or annular strictures involving both intra- and extrahepatic bile ducts.
- At least one of the following clinical manifestations: biochemical evidence of cholestasis (primarily elevated ALP and/or GGT); clinical or histological evidence of coexisting inflammatory bowel disease (IBD); or liver histology showing periductal inflammation with fibrosis (i.e., periductal "onion-skin" appearance).
- Exclusion of secondary sclerosing cholangitis due to other etiologies.
- For small-duct PSC, diagnosis must meet the following criteria:
- Biochemical evidence of cholestasis with no significant abnormalities on recent biliary imaging.
- Liver histology showing typical PSC changes as described above (periductal inflammation with fibrosis / "onion-skin" appearance).
- Exclusion of other causes of cholestasis. Patients must have received a standard regimen of UDCA for ≥3 months (at a dose of no less than 13-15 mg/kg/day). At screening, ALP ≥1.5 × ULN or GGT ≥5 × ULN.
Who cannot join
- Patients who meet any of the following criteria will be excluded from enrollment:
- Known concurrent or history of other hepatobiliary diseases, including but not limited to: active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; complete biliary obstruction; acute cholecystitis or symptomatic cholelithiasis; suspected or confirmed hepatocellular carcinoma (HCC) or cholangiocarcinoma.
- Child-Pugh Class C cirrhosis; evidence of end-stage liver disease, including: history of liver transplantation or being on the liver transplant waiting list; Model for End-Stage Liver Disease (MELD) score >20; severe portal hypertension complications (including severe gastric or esophageal varices, refractory or diuretic-resistant ascites, history of variceal bleeding); or other serious cirrhosis-related complications (spontaneous bacterial peritonitis, hepatic encephalopathy, hepatorenal syndrome, hepatopulmonary syndrome).
- Total bilirubin >10 × upper limit of normal (ULN).
- Serum creatinine ≥1.5 × ULN and creatinine clearance <60 mL/min.
- Platelet count <50 × 10⁹/L.
Show all 16Show fewer
- International normalized ratio (INR) >1.5.
- Serum albumin <3.0 g/dL.
- Use of moderate or strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) within 14 days prior to the first dose of study drug or planned use throughout the study period.
- Presence of diseases that may cause non-hepatic elevation of ALP (e.g., Paget's disease of bone) or any condition with an anticipated life expectancy of less than 2 years.
- Known drug abuse or alcohol abuse within 6 months prior to the first dose of study drug, defined as weekly alcohol consumption exceeding 14 standard drinks (1 standard drink equivalent to 360 mL beer, 45 mL of 40% distilled spirits, or 150 mL wine).
- Unstable concomitant diseases or use of concomitant medications that cannot be maintained on a stable regimen throughout the clinical study period.
- Pregnant women, women planning to become pregnant, breastfeeding women, or fertile patients (male or female) who are unwilling to use at least one effective method of contraception from the time of signing informed consent until 30 days after the last dose of study drug.
- Participation in any other interventional clinical trial and receipt of any investigational product within 3 months prior to the first dose of study drug.
- Positive results for human immunodeficiency virus antibodies (HIV Ab) or Treponema pallidum antibodies (TP Ab).
- Any other condition that, in the investigator's judgment, would preclude the patient's participation in this study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
RenJi Hospital
Shanghai, Shanghai Municipality, 200001
Min Lian, MD, +8615800744783, sophialian24@163.com
About this study
Official title: Evaluation of the Safety and Efficacy of Upadacitinib in the Treatment of Atopic Dermatitis With Moderate to Severe Itching and Refractory Autoimmune Related Cholangitis: a Single Arm, Exploratory Clinical Study
Cholestatic liver diseases are characterized by jaundice, pruritus, and elevated levels of alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT). Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) represent the major autoimmune-driven entities within this category. Without effective intervention, these conditions may progress to liver failure and even death. Ursodeoxycholic acid (UDCA), the first-line therapy for PBC, has been shown to improve prognosis; however, 20%-40% of patients exhibit an inadequate biochemical response. For PSC, no clearly effective pharmacologic agent is currently available. In refractory patients, pruritus often progressively worsens, severely impairing quality of life and treatment adherence, underscoring an urgent need for novel therapeutic approaches that simultaneously address disease control and itch relief.
Autoimmune-associated cholangitis frequently coexists with atopic dermatitis, and in a subset of patients, pruritus may be compounded by dermatologic factors. The pruritus of atopic dermatitis involves the JAK-STAT signaling pathway, which not only serves as a convergent node for pruritic signals but also constitutes a key downstream hub in the immune dysregulation characteristic of cholangitis. Inhibition of this pathway is therefore hypothesized to alleviate pruritus and modulate aberrant immune responses. Case reports have suggested that upadacitinib, a selective JAK inhibitor, may improve biochemical parameters in refractory PBC and exhibit potential anti-fibrotic effects.
To this end, investigators plan to conduct an exploratory clinical study to systematically evaluate the safety and efficacy of upadacitinib in patients with atopic dermatitis complicated by moderate-to-severe pruritus and refractory autoimmune-associated cholangitis.
- Conditions
- Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Atopic Dermatitis (AD)
- Being tested
- Upadacitinib 15 MG
- Keywords
- Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Atopic Dermatitis (AD), pruritus, upadacitinib, cholangitis, bile duct diseases, biliary tract diseases, Digestive System Diseases, Cirrhosis, Biliary, Cholangitis, Biliary, Cholangitis, Sclerosing
- Medical subject headings
- Liver Cirrhosis, Biliary, Cholangitis, Sclerosing, Dermatitis, Atopic, Pruritus, Cholangitis, Bile Duct Diseases, Biliary Tract Diseases, Digestive System Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Upadacitinib 15 MGDrug
This is a single-arm, open-label, fixed-dose exploratory clinical trial. All eligible subjects who meet the inclusion and exclusion criteria will receive a uniform, fixed-dose regimen of upadacitinib in combination with background therapy, without a concurrent control group. The administered dose is 15 mg once daily (QD), which falls within the recommended dose range for atopic dermatitis as approved in the upadacitinib Chinese package insert (product labeling). This study will not investigate alternative dosage regimens, nor will it evaluate the efficacy or safety of off-label dose levels.
| Study group | Role | What they receive |
|---|---|---|
| Patients with atopic dermatitis complicated by moderate-to-severe pruritus and refractory PBC/PSC | Experimental | Not described Receives: Drug: Upadacitinib 15 MG |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pruritus of atopic dermatitis
Change from baseline in the Visual Analogue Scale (VAS) score for pruritus during the study period.
Measured: At screening, week 12 and week 24
Biochemical composite endpoint of autoimmune-associated cholangitis
Proportion of patients achieving the biochemical composite endpoint at Week 12 and Week 24, defined as a ≥30% reduction in alkaline phosphatase (ALP) from baseline without elevation in direct bilirubin (DB).
Measured: At week 12 and week 24
Degree of liver fibrosis
Change from baseline in liver stiffness measurement assessed by transient elastography (FibroTouch/FibroScan).
Measured: At screening and week 24
Secondary outcomes (6)
Blood eosinophil count
Change from baseline in peripheral blood eosinophil count during the study period.
Measured: At screening and week 24
Peripheral blood immune cell subpopulations
Change from baseline in peripheral blood immune cell subpopulations during the study period.
Measured: At screening and week 24
Serum immunoglobulin levels
Change from baseline in serum immunoglobulin levels (IgG, IgM, IgA) during the study period.
Measured: At screening, week 12 and week 24
Liver function
Percentage change from baseline in serum levels of alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin (TB), direct bilirubin (DB) , alanine aminotransferase (ALT), aspartate aminotransferase (AST) and albumin (ALB) during the study period.
Measured: At screening, week 4, week 12 and week 24
UK-PBC score
Change from baseline in UK-PBC score at Week 12 and Week 24 in patients with primary biliary cholangitis
Measured: At screening, week 12 and week 24
PBC GLOBE score
Change from baseline in PBC GLOBE score at Week 12 and Week 24 in patients with primary biliary cholangitis
Measured: At screening, week 12 and week 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2026
- Study start1 Jun 2026 (estimated)
- Primary completion30 Nov 2027 (estimated)
- Study completion31 May 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Primary Biliary Cholangitis (PBC)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- single-arm study
- Masking
- None (open label)
- Enrolment
- 44 participants (estimated)
Sponsor and investigators
- Lead sponsor
- RenJi Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, ma xiong, RenJi Hospital
- Investigators
- Xiong Ma, MD, PhD, Principal investigator, RenJi Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07678645
- Sponsor's protocol ID
- ARC2026CH001
- Status last verified
- Jun 2026
- First submitted
- 24 Jun 2026
- Last updated
- 1 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Not sharing IPD. After this study is completed, we are welcome to share the basic demographics and clinical outcomes of this study.